相关实验视频

Updated: Jul 8, 2025

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

乳腺癌新辅助化疗后立即重建的治疗效果:系统性审查和元分析

Gang Li¹, Hongxiang Ji¹, Jiang Li¹

¹Department of General Surgery, The Chenggong Hospital Affiliated to Xiamen University, Xiamen, China.

Frontiers in oncology

|December 11, 2023

概括

在新辅助化疗后进行立即重建的乳房切除术不会影响存活率,但可能会略微增加短期手术并发症. 在立即重建的乳腺切除术和单独的乳腺切除术之间,长期并发症没有显著不同.

科学领域:

在瘤学瘤学.
手术瘤学手术瘤学
乳腺癌研究研究乳腺癌研究

背景情况:

在完成新辅助化疗 (NAC) 的乳腺癌患者中,评估立即重建乳腺切除术 (MT+IR) 与单独乳腺切除术 (MT) 的安全性和瘤结果.
在NAC后的环境中,评估MT+IR和MT之间手术并发症和术后生存率的差异.

研究的目的:

系统地评估和比较手术并发症和术后生存率.
评估在完成新辅助化疗的乳腺癌患者中立即重建的安全性和有效性.

主要方法:

进行了对队列研究的综合元分析.
在主要数据库 (PubMed,Embase,Cochrane图书馆,WanFang,CNKI) 进行了搜索,截至2023年5月25日.
数据提取和偏差评估由两位研究人员独立进行,并使用Revman 5.3软件进行元分析.

主要成果:

分析了12项涉及7378名患者的研究.
立即重建的乳腺切除显示,手术并发症的44%增加是不显著的 (RR=1.44,P=0.06).
在MT+IR组 (RR=1.23,P=0.05) 观察到短期并发症的显著增加 (一年内),整体存活率,无病存活率,局部无复发存活率或远程无转移存活率没有显著差异.

结论:

立即重建的乳腺切除术不会对后NAC乳腺癌患者的术后生存率产生负面影响.
与单独的MT相比,MT+IR与短期外科并发症的轻微增加有关,但没有显著的长期并发症.

关键词:

乳腺癌乳腺癌乳腺癌立即进行重建和重建.进行乳房切除术,即乳房切除术.这是一个元分析.新辅助性化疗是一种新辅助性化疗.

更多相关视频

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...